Clinical significance of atypical glandular cells in Pap tests: An analysis of more than 3000 cases at a large academic women's center

Cancer Cytopathology

Volumn 124, Issue 8, 2016, Pages 589-595

  Pradhan, Dinesh ^a   Li, Zaibo ^a,b   Ocque, Rebecca ^a,c   Patadji, Stell ^a   Zhao, Chengquan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c Eastern Great Lakes Pathology   (United States)

Author keywords

atypical glandular cell; cervical cancer screening; glandular neoplasia; histological follow up; Papanicolaou (Pap) test

Indexed keywords

ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL ENDOCERVICAL CELL; ATYPICAL GLANDULAR CELL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CELLS BY BODY ANATOMY; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; MIDDLE AGED; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VERY ELDERLY; YOUNG ADULT;

EID: 84982189600     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21724     Document Type: Article

References (41)

1. Wood MD, Horst JA, Bibbo M. Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based Pap tests: a review. Diagn Cytopathol. 2007;35:12–17.
2. Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the cervix diagnosed as a consequence of cytologic screening. Acta Cytol. 2003;47:167–171.
3. Syrjanen K. Is improved detection of adenocarcinoma in situ a key to reducing the incidence of endocervical adenocarcinoma? Acta Cytol. 2004;48:591–594.
4. Mitchell H, Hocking J, Saville M. Cervical cytology screening of women diagnosed with adenocarcinoma in situ of the cervix: a case control study. Acta Cytol. 2004;48:595–600.
5. Kalir T, Simsir A, Demopoulos HB, Demopoulos RI. Obstacles to early detection of endocervical adenocarcinoma. Int J Gynecol Pathol. 2005;24:399–403.
6. Simsir A, Hwang S, Cangiarella J, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and prediction of cell of origin. Cancer. 2003;99:323–330.
7. Lee KR, Darragh TM, Joste NE, et al. Atypical glandular cells of undetermined significance (AGUS): interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol. 2002;117:96–102.
8. Sherman ME, Dasgupta A, Schiffman M, Nayar R, Solomon D. The Bethesda Interobserver Reproducibility Study (BIRST): a Web-based assessment of the Bethesda 2001 system for classifying cervical cytology. Cancer. 2007;111:15–25.
9. Raab SS, Geisinger KR, Silverman JF, Thomas PA, Stanley MW. Interobserver variability of a Papanicolaou diagnosis of atypical glandular cells of undetermined significance. Am J Clin Pathol. 1998;110:653–659.
10. Zhao C, Austin RM, Pan J, et al. Clinical significance of atypical glandular cells in conventional Pap smears in a large, high-risk, U.S. West Coast minority population. Acta Cytol. 2009;53:153–159.
11. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006;107:701–708.
12. Andrae B, Kermetli L, Sparen P, et al. Screening preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622–629.
13. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–891.
14. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer. 2003;99:336–341.
15. Mitchell H, Giles G, Medley G. Accuracy and survival benefit of cytological prediction of endometrial carcinoma on routine cervical smears. Int J Gynecol Pathol. 1993;12:34–40.
16. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128:1224–1229.
17. Schoolland M, Segal A, Allpress S, Miranda A, Frost FA, Sterrett GF. Adenocarcinoma in situ of the cervix. Cancer. 2002;96:330–337.
18. Ruba S, Schoolland M, Allpress S, Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer. 2004;102:280–287.
19. Geldenhuys L, Murray ML. Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol. 2007;51:47–50.
20. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer. 2001;93:8–15.
21. Diaz-Montes TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol. 2007;104:366–371.
22. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105:494–500.
23. Barreth D, Faught W, Schepansky A, Johnson G. The relationship between atypical glandular cells of undetermined significance on Pap smear and a clinically significant histologic diagnosis. J Obstet Gynaecol Cancer. 2004;26:867–870.
24. Lai CR, Hsu CY, Tsay SH, Li AF. Clinical significance of atypical glandular cells by the 2001 Bethesda System in cytohistologic correlation. Acta Cytol. 2008;52:563–567.
25. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC. Reclassification and analysis of clinical significance of atypical glandular cells on ThinPrep using Bethesda 2001: Geneva experience. Swiss Med Wkly. 2007;137:635–641.
26. Wang J, Andrae B, Sundstrom K, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ. 2016;352:i276.
27. Miller RA, Mody DR, Tams KC, Thrall MJ. Glandular lesions of the cervix in clinical practice: a cytology, histology, and human papillomavirus correlation study from 2 institutions. Arch Pathol Lab Med. 2015;139:1431–1436.
28. Chen L, Booth CN, Shorie JA, Brainard JA, Zarka MA. Atypical endometrial cells and atypical glandular cells favor endometrial origin in Papanicolaou cervicovaginal tests: correlation with histologic follow-up and abnormal clinical presentations. Cytojournal. 2014;11:29.
29. Ulker V, Numanoglu C, Akyol A, et al. Analyses of atypical glandular cells re-defined by the 2006 Bethesda System: histologic outcomes and clinical implication of follow-up management. Eur J Gynaecol Oncol. 2013;34:457–461.
30. Cheng WF, Chen YL, You SL, et al. Risk of gynaecological malignancies in cytologically atypical glandular cells: follow-up study of a nationwide screening population. BJOG. 2011;118:34–41.
31. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol. 2010;115:243–248.
32. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–2129.
33. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology–Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–355.
34. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–846.
35. Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer. 2001;93:1–7.
36. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. CA Cancer J Clin. 2012;62:147–172.
37. Serdy K, Yildiz-Aktas I, Li Z, Zhao C. The value of Papanicolaou tests in the diagnosis of endometrial carcinoma: a large study cohort from an academic medical center. Am J Clin Pathol. 2016;145:350–354.
38. Xing W, Hou AY, Fischer A, Owens CL, Jiang Z. The Cellient automated cell block system is useful in the differential diagnosis of atypical glandular cells in Papanicolaou tests. Cancer Cytopathol. 2014;122:8–14.
39. Zhao C, Li Z. Automated cell block system for atypical glandular cells of cervical cytology: is it feasible? Cancer Cytopathol. 2014;122:5–7.
40. Zhao C, Florea A, Austin RM. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med. 2010;134:103–108.
41. Chen L, Yang B. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer. 2008;114:236–241.